Real-World Evidence And The Quest For European Market Access

Real-world evidence promises to solve many problems inherent in getting a drug to patients at a good price. It could slash development costs and help make the reimbursement case to payers. But there are challenges for companies that want to exploit real-world evidence to get their drug to patients in Europe.

IV1610_RWE_1200x675

Getting an innovative new drug to patients and convincing payers to pay a good price is no easy feat, as pharma companies know. Real-world evidence has for some time been touted as a remedy for quicker approvals, better discussions with payers and flexible reimbursement agreements. Even though advances in digitization mean that data are potentially much more accessible, real-world evidence has yet to fulfill its promise. A lack of trust in what will happen to patient data, poor approaches to market access and concerns over whether the data are fit for purpose are just some of the challenges in Europe.

Cash-strapped payers are balking at the prices of many pharmaceuticals and thinking hard about whether they want to pay. Real-world...

More from Market Access

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.